# CellSight

The site is in English only.
Clinical trial studies are listed on /clinical-trials.
Scientific publications and presentations are listed on /publications.

## Documentation Sets

## Overview

CellSight Technologies, Inc.
Headquarters: 185 Berry Street, Suite 350, San Francisco, CA 94107
Contact: contact@cellsighttechnologies.com | 650-799-1589
LinkedIn: https://www.linkedin.com/company/cellsight-technologies-inc-/
X / Twitter: https://x.com/cellsightt/

## Business Areas

- Clinical trial design, recruitment, and management
- Cell-based therapy research and development
- Peer-reviewed scientific publication
- Conference presentations and professional knowledge sharing
- Research articles and scientific updates

## Industries

- Biotechnology
- Life Sciences
- Clinical Research
- Cell Therapy
- Medical Research

## Capabilities

- Clinical trial recruitment (open and closed studies)
- Peer-reviewed publication of scientific findings
- Scientific presentations at professional conferences
- Technology-driven approach to cell-based therapies
- Team-based research with experts in cell biology

## Keywords

CellSight, CellSight Technologies, cell therapy, cell-based therapy, clinical trials, biotech, biotechnology, life sciences, scientific research, publications, presentations, San Francisco, clinical research

## Pages

- [Technology](https://www.cellsighttech.com/technology)
- [Clinical Trials](https://www.cellsighttech.com/clinical-trials)
- [Publications](https://www.cellsighttech.com/publications)
- [About Us](https://www.cellsighttech.com/about)

## Clinical Studies

### Assessment of PET Tracers to Evaluate T Cell Change and Activation in Relation to Immunotherapy Treatment Response in Non-Small Cell Lung Cancer 

_Idris Bahce M.D., Ph.D. I Amsterdam UMC · 2024-02-02 · Open for recruitment_

This PET imaging trial will compare two promising T cell PET tracers alongside the pathological analysis of the resected tumor. Following chemo-immunotherapy, NSCLC patients will undergo two PET scans shortly before their surgery.

### [18F]F-AraG PET imaging of Non Small Cell Lung Cancer patients undergoing checkpoint inhibitor immunotherapy

_Yuji Nakamoto M.D. Ph.D. and Tomomi W Nobashi M.D. I Kyoto University · 2023-01-02 · Open for recruitment_

This study explores tumoral uptake of [18F]F-AraG and its association with the treatment effect of immune checkpoint inhibitors for stage 4 NSCLC patients. [18F]F-AraG PET/CT scanning will be performed twice per patient, pre and post start of immunotherapy. The uptake difference in tumor and associated lymphoid organs will be considered for the analysis, as well as the correlation with the expression of CD8, PD-1 and Treg markers in immunohistochemistry. CellSight is providing [18F]F-AraG precursor free of charge.

### Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG 

_Muhammad Furqan M.D. I Holden Comprehensive Cancer Center · 2023-01-01 · Open for recruitment_

This pilot study uses [18F]F-AraG PET imaging to evaluate the immunological response to inhibitor therapy (CkIT) in patients with advanced NSCLC tumors.

### Test-retest Evaluation of [18F]F-AraG PET

_John Sunderland Ph.D. and Muhammad Furqan M.D. I Holden Comprehensive Cancer Center · 2023-01-01 · Open for recruitment_

This pilot study aims to evaluate the test-retest variability of [18F]F-AraG-PET imaging in patients with advanced NSCLC tumors.

### A Clinical Imaging Study of the Changes in [18F]F-AraG Uptake Following Anti-PD-1 Therapy in Non-small Cell Lung Cancer (SHARP)

_Idris Bahce M.D., Ph.D. I Amsterdam UMC  · 2022-01-01 · Open for recruitment_

The aim of the SHARP trial is to investigate changes in [18F]F-AraG uptake following Anti-PD-1 therapy in patients with non-small cell lung cancer (NSCLC).

### A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors

_Shivaani Kummar M.D. , Erik Mittra M.D. and Carina Mari Aparici M.D. I Oregon Health and Science University and  Stanford University · 2022-01-01 · Open for recruitment_

In this study, patients with advanced solid tumors will undergo [18F]F-AraG PET/CT imaging to assess for changes in tracer uptake following treatment with CkIT.

###  [18F]F-AraG/Total Body PET Imaging and Healthy Subjects and Lung Cancer Patients

_Simon R Cherry Ph.D. I University of California, Davis · 2021-05-01 · Open for recruitment_

In this pilot study, healthy volunteers and patients with Non-Small Cell Lung Cancer will undergo [18F]F-AraG dynamic imaging on the uEXPLORER total body PET/CT scanner to obtain preliminary data regarding pharmacokinetics and early biodistribution images.

### Imaging of T-cell Activation With [18F]F-AraG in Advanced Non-Small Cell Lung Cancer (NSCLC)

_Millie Das M.D., Minal Vasanawala M.D., and Deepti Behl M.D. I Palo Alto Veteran’s Affairs and Sutter Medical Center · 2021-04-01 · Open for recruitment_

This is a pilot study using [18F]F-AraG PET imaging to evaluate the immunological response to checkpoint inhibitor therapy (CkIT) in patients with advanced NSCLC tumors at multiple study sites.

### Imaging Immune Activation in COVID-19

_Timothy Henrich M.D. I University of California, San Francisco · 2021-03-01 · Open for recruitment_

This is a single arm exploratory imaging study involving up to two intravenous microdoses of [18F]F-AraG (the second tracer dose is optional) followed by whole-body PET-CT imaging in participants with convalescent COVID-19.

### 18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma

_David Miklos M.D., Ph.D. I Stanford University · 2021-01-02 · Open for recruitment_

This is a pilot study in adult subjects with aggressive B-cell lymphoma who will receive commercial or research CAR T cell therapy as anticancer treatment.

###  [18F]F-AraG PET Imaging to Visualize Tumor Infiltrating T-cell Activation in Non-small Cell Lung Cancer (ATTAIN)

_Idris Bahce M.D., Ph.D. I Amsterdam UMC  · 2021-01-01 · Open for recruitment_

The aim of the ATTAIN trial is to investigate the pharmacokinetic characteristics of [18F]F-AraG by performing a full kinetic modelling, assess test-retest (TRT) variability and to correlate the tumor tracer uptake with the pathological assessment.

### PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC)

_Martin Pomper M.D., Ph.D. I Johns Hopkins University · 2021-01-01 · Recruitment closed_

This is a prospective clinical trial in patients with non-small cell lung cancer (NSCLC) undergoing PD-1/PD-L1-directed therapy. This research is being done to find out if [18F]F-AraG is a helpful imaging agent for detecting changes in cancer's anti-tumor immune response levels for NSCLC patients who will receive a cancer immunotherapy regimen.

### Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab

_Diwakar Davar M.D., M.Sc. I University of Pittsburgh Medical Center · 2020-01-01 · Recruitment closed_

The main goal of this research study is to determine how nivolumab and nivolumab/Vidutolimod (CMP-001) combination affect the likelihood of destroying melanoma involving lymph node and/or in-transit/satellite areas.

### Biodistribution and Kinetics of 18F-AraG in Non-Small Cell Lung Cancer

_Dustin Osborne Ph.D. I University of Tennessee · 2019-01-01 · Recruitment closed_

This study is to assess the biodistribution and kinetics of [18F]F-AraG in non-small cell lung cancer patients undergoing immunotherapy with and without adjuvant radiation therapy.

### Imaging Immune Activation in HIV by PET-MR

_Timothy J Henrich M.D. I University of California, San Francisco · 2018-01-01 · Open for recruitment_

This study involves one intravenous microdose of [18F]F-AraG followed by whole-body positron emission tomography-magnetic resonance (PET-MR) imaging in HIV infected individuals to determine the anatomical distribution of the PET tracer.

### Detection of Graft Versus Host Disease With [18F]F-AraG

_Sanjiv Gambhir M.D., Ph.D. I Stanford University · 2018-01-01 · Recruitment closed_

This study determines the utility of in vivo imaging with [18F]F-AraG to identify sites of Graft Versus Host Disease (GVHD) in patients highly suspected of having acute GVHD who require systemic therapy, and patients at high risk for developing acute GVHD.

### Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1

_Lawrence Fong M.D. I University of California, San Francisco · 2017-03-01 · Recruitment closed_

This phase II trial studies how well [18F]F-AraG PET/MR imaging works in measuring clinical response to atezolizumab or patients with cancer receiving standard of care Anti-PD-1/L1.

### Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

_A. Dimitrios Colevas M.D. I Stanford University · 2017-02-01 · Recruitment closed_

This is a cross-sectional imaging and correlative biomarker study in patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN). Two whole body PET/CT images with [18F]F-AraG, blood samples, and tissue biopsies will be collected from patients.

###  [18F]FAraG PET Imaging for Analysis of Biodistribution in Cancer Patients Expected to Undergo Immunotherapy and/or Radiation Therapy

_Robert R Flavell M.D., Ph.D. I UCSF Department of Radiology and Biomedical Imaging · 2017-01-01 · Recruitment closed_

This is a Phase 1 study is to visualize biodistribution of [18F]F-AraG (VisAcT) in cancer patients expected to undergo immunotherapy and/or radiation therapy.

### Study of Kinetics, Dosimetry & Safety of [18F]F-AraG, a Positron Emission Tomography Imaging Tracer in Healthy Humans

_Henry Vanbrocklin Ph.D. I University of California, San Francisco · 2015-01-01 · Recruitment closed_

The goal of this study is to visualize biodistribution of [18F]F-AraG through time in healthy human volunteers.

## Publications

### [18F]F-AraG Uptake in Vertebral Bone Marrow May Predict Survival in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-(L)1 Immunotherapy

_Levi J. et al. · 2024-10-24_

URL: https://jnm.snmjournals.org/content/early/2024/10/24/jnumed.124.268253

Journal of Nuclear Medicine, 2024.

### Pharmacokinetic analysis and simplified uptake measures for tumour lesion [18F]F-AraG PET imaging in patients with non-small cell lung cancer

_Wijngaarden J. et al. · 2024-10-08_

URL: https://link.springer.com/article/10.1007/s00259-024-06931-3

European Journal of Nuclear Medicine and Molecular Imaging, 2024.

### Enrichment of novel CD3+F4/80+ cells in brown adipose tissue following adrenergic stimulation

_Chae H. et al. · 2024-08-26_

URL: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1455407/full  

Frontiers Immunology, 2024.

### A feasibility study of [18F]F-AraG positron emission tomography (PET) for cardiac imaging - myocardial viability in ischemia-reperfusion injury model

_Shrestha U. et al. · 2024-07-26_

URL: https://link.springer.com/article/10.1007/s11307-024-01932-y

Molecular Imaging and Biology, 2024.

### Tissue-based T cell activation and viral RNA persist for up to 2 years after SARS-CoV-2 infection

_Peluso M.J. et al. · 2024-07-03_

URL: https://www.science.org/doi/10.1126/scitranslmed.adk3295?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

Science Translational Medicine, 2024.

### [18F]F-AraG imaging reveals association between neuroinflammation and brown- and bone marrow adipose tissue

_Levi J. et al. · 2024-07-01_

URL: https://www.nature.com/articles/s42003-024-06494-x

Nature Communications Biology, 2024.

### Total-Body Dynamic Imaging and Kinetic Modeling of [18F]F-AraG in Healthy Individuals and a Non–Small Cell Lung Cancer Patient Undergoing Anti–PD-1 Immunotherapy

_Omidivari N. et al. · 2023-09-03_

URL: https://jnm.snmjournals.org/content/65/9/1481.long

Journal of Nuclear Medicine, 2024.

### The other immuno-PET: Metabolic tracers in evaluation of immune responses to immune checkpoint inhibitor therapy for solid tumors.

_Levi J. and Song H. · 2023-01-01_

URL: https://www.frontiersin.org/articles/10.3389/fimmu.2022.1113924/full

Frontiers in Immunology, 2023.

### Biodistribution of a Mitochondrial Metabolic Tracer, 18F-FAraG, in Healthy Volunteers.

_Levi J, Duan H, Yaghoubi S, Packiasamy J, Huynh L, Lam T, Shaikh F, Behera D, Song H, Blecha J, Jivan S, Seo Y, VanBrocklin H. · 2022-01-01_

URL: https://www.hindawi.com/journals/moi/2022/3667417/

Molecular Imaging. Volume 2022.

### Longitudinal imaging of T-cells and inflammatory demyelination in a preclinical model of multiple sclerosis using 18F-FAraG PET and MRI.

_Guglielmetti C, Levi J, Huynh TL, Tiret B, Blecha J, Tang R, Van Brocklin HF, Chaumeil MM. · 2021-04-09_

URL: https://pubmed.ncbi.nlm.nih.gov/33837066/

J Nucl Med. 2021 Apr 9:jnumed.120.259325.

### 18F-FAraG PET for CD8 Profiling of Tumors and Assessment of Immunomodulation by Chemotherapy.

_Levi J, Goth S, Huynh L, Lam T, Huynh T.L., Schulte B, Packiasamy JA.  · 2020-11-06_

URL: https://pubmed.ncbi.nlm.nih.gov/33158906/

2020 Nov 6;jnumed.120.249078.

### Imaging of activated T cells as an early predictor of immune response to anti-PD-1 therapy.

_Levi J, Lam T, Goth SR, Yaghoubi S, Bates J, Ren G, Jivan S, Huynh TL, Blecha JE, Khattri R, Schmidt KF, Jennings D, VanBrocklin H · 2019-05-07_

URL: http://cancerres.aacrjournals.org/content/early/2019/05/07/0008-5472.CAN-19-0267.long

Cancer Res. 2019 May 7. pii: canres.0267.2019.

### A PET imaging strategy to visualize activated T cells in acute graft-versus-host disease elicited by allogenic hematopoietic cell transplant.

_Ronald JA, Kim BS, Gowrishankar G, Namavari M, Alam IS, D'Souza A, Nishikii H, Chuang HY, Ilovich O, Lin CF, Reeves R, Shuhendler A, Hoehne A, Chan CT, Baker J, Yaghoubi SS, VanBrocklin HF, Hawkins R, Franc BL, Jivan S, Slater JB, Verdin EF, Gao KT, Benjamin J5, Negrin R, Gambhir SS · 2017-06-01_

URL: http://cancerres.aacrjournals.org/content/77/11/2893.long

Cancer Res. 2017 Jun 1;77(11):2893-2902.

### In vivo PET imaging of the activated immune environment in a small animal model of inflammatory arthritis.

_Franc BL, Goth S, MacKenzie J, Li X, Blecha J, Lam T, Jivan S, Hawkins RA, VanBrocklin H.  · 2017-01-01_

URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480631/

Mol Imaging. 2017 Jan 1;16:1536012117712638.

### Synthesis of 2'-deoxy-2'-[18F]fluoro-9-β-D-arabinofuranosylguanine: a novel agent for imaging T-cell activation with PET

_Namavari M, Chang YF, Kusler B, Yaghoubi S, Mitchell BS, Gambhir SS · 2011-10-13_

URL: https://link.springer.com/article/10.1007%2Fs11307-010-0414-x

Mol Imaging Biol. 2011 Oct;13(5):812-8.

## Presentations

### 4th International congress on inflammation and infection imaging 2024 Rome

_Levi J. · 2024-12-06_

[18F]F-AraG in monitoring response and predicting outcomes in patients with cancer treated with PD-(L)1 therapy

### WMIC 2024 Montréal

_Levi J. · 2024-09-09_

[18F]F-AraG uptake in the vertebral bone marrow predicts survival in immunotherapy treated non-small cell lung cancer patients

### SNMMI 2024 Toronto

_Levi J.  · 2024-06-10_

Simultaneous imaging of activated lymphocytes and adipocytes with [18F]F-AraG reveals association between neuroinflammation and brown- and bone marrow adipose tissue

### SNMMI 2024 Toronto

_Nobashi T. · 2024-06-09_

Psyhological Uptake of 18F-AraG immunoPET in Non-Small Cell Lung Cancer Patients in Japan.

### Immunology 2024 Chicago

_Chae H-D. · 2024-05-05_

Emergence of novel CD3+ Macrophages in Brown Adipose Tissue Following Adrenergic Stimulation

### EMIM 2024 Porto

_Guglielmetti C. · 2024-03-15_

18F-AraG PET imaging of activated T cells differentiates between acute and chronic lesions in a multiple sclerosis model

### EMIM 2024 Porto

_Wijngaarden J.E. · 2024-03-15_

Pharmacokinetic analysis and simplified uptake measures for tumor lesion [18F]F-AraG PET imaging in patients with non-small cell lung cancer

### EMIM 2024 Porto

_Levi J. · 2024-03-13_

18F-AraG Accumulates in Metabolically Active Brown- and Bone Marrow Adipose Tissue
See more section

### CROI 2024 Colorado 

_Henrich T. · 2024-03-04_

[18F]F-AraG PET Imaging Reveals Unique Tissue T Cell Activation Patterns Across HIV Infection States

### SNNMI 2023 Chicago

_Shrestha U.  · 2023-01-01_

A novel mitochondrial-targeted [18F]F-AraG positron emission tomography (PET) biomarker for early diagnosis and monitoring of cardiotoxicity.

### iSRS 2023 Hawaii

_Blecha J. · 2023-01-01_

Synthesis of [18F]F-AraG Using a Second-Generation Precursor and Its Utility Across Multiple Radiochemistry Platforms.

### Immuno-Oncology Symposium (2022), Center for Translation Cancer Research, Western University

_2022-01-01_

Towards in vivo Immunoscore: Assessing Systemic Immune Response with [18F]F-AraG.

### SNNMI 2021 poster presentation.

_2021-01-01_

URL: https://jnm.snmjournals.org/content/62/supplement_1/1281

PET imaging of activated T cells in pancreatic tumors with [18F]F-AraG.

### WMIC 2021 Spotlight Session – Activity-based Sensing.

_2021-01-01_

The other ImmunoPET: Visualizing T cell Activity with [18F]F-AraG.

### SITC 2021 poster presentation.

_2021-01-01_

URL: https://jitc.bmj.com/content/9/Suppl_2/A52

AI-assisted whole-body assessment of immunotherapy response using [18F]F-AraG, a PET agent for activated T cells.

### SNNMI 2020 Infection Session.

_H. VanBrocklin · 2020-01-01_

Henry VanBrocklin presented: Imaging viral load and T cell activation in HIV: tools for cure development.

### WMIC 2020 Cell Tracking Session

_C. Guglielmett · 2020-01-01_

Caroline Guglielmetti presented: Longitudinal imaging of activated T cells and inflammatory demyelination using MRI and [18F]F-AraG PET in a novel multiple sclerosis model.

### WMIC 2020 Immuno-Oncology Session.

_J. Levi · 2020-01-01_

Jelena Levi presented: [18F]F-AraG PET for CD8 profiling of tumors and assessment of immunomodulation by chemotherapy.

### UCSF Annual Imaging Research Symposium 2020

_C. Guglielmetti · 2020-01-01_

Caroline Guglielmetti presented: Improving brain lesion characterization in a multiple sclerosis model using [18F]F-AraG PET and MR imaging of T cells and inflammatory demyelination.

### WMIC 2019 Oncology Session. 

_2019-01-01_

Poster presentation: Imaging of activated T cells as an early predictor of immune response to anti-PD-1 therapy.

### IBA Radiopharma Webinar 2019 The role of PET imaging in Immuno-Oncology.

_J. Levi · 2019-01-01_

URL: https://www.gotostage.com/channel/c91227af67ff4be2ad68ba39372dabdb/recording/a9bc8a273e68482c9ba4a8e3d5ed2ab5/watch?source=CHANNEL

Jelena Levi presented: ImmunoPET for imaging immune responses - 18F labeled agents.

### 2018 American Society of Clinical Oncology Conference.

_2018-01-01_

Poster presentation: A study to evaluate immunological response to PD-1 inhibition in squamous cell carcinoma of the head and neck (SCCHN) using novel PET imaging with [18F]F-AraG.

### WMIC 2018 Imaging in Cell and Immune Therapy (ICIT)/Endogenous Immunity and Microenvironment Workshop.

_J. Levi · 2018-01-01_

Jelena Levi presented: Evaluating immunological response using T cell specific PET imaging agent, [18F]F-AraG, in preclinical models and in clinical trials.

## Articles

### Unlocking the mitochondrial axis: [18F]F-AraG as a cross-disease imaging biomarker in immuno-oncology, cardiology and neuroinflammation.

_2025-06-12_

Dr. Jelena Levi, CellSight’s CSO, delivered the 2025 Aruna Bodapati Gambhir Lecture as part of Stanford’s Molecular Imaging Seminar Series. She highlighted the unique capabilities of [¹⁸F]F‑AraG to image both immune activation and mitochondrial function, underscoring its broad potential as a cross-disease biomarker platform with broad translational impact.

### Role of [18F]F-AraG in assessing systemic immunity

_2025-02-08_

An overview of preclinical and clinical investigations of [18F]F-AraG in evaluating systemic immunity was presented at the Indo-American Society of Nuclear Medicine (IASNM) Radiant Flashpoints Educational Web-Series, organized in honor of Dr. Sanjiv Sam Gambhir

### [18F]F-AraG in monitoring response and predicting outcomes in patients with cancer treated with PD-(L)1 therapy

_2024-12-06_

[18F]F-AraG’s ability to evaluate immune contexture within the tumor microenvironment as well as systemic immunity in patients with cancer treated with immunotherapy was presented at the 4th International congress on inflammation and infection imaging in Rome, Italy.

### [18F]F-AraG uptake in the vertebral bone marrow predicts survival in immunotherapy treated non-small cell lung cancer patients

_2024-09-09_

The study by Dr. Levi et al. was recognized as one of the top abstracts at the 2024 WMIC in Montreal, Canada.

### [18F]F-AraG reveals long-term immune system activation following COVID-19 infection

_2024-07-03_

The USCF study by Peluso M.J. et al., which reported T cell activation and viral persistence in several tissues in post-acute COVID-19 participants, has made the cover of Science Translational Medicine, Volume 16, Issue 754.

### [18F]F-AraG imaging reveals association between neuroinflammation and brown- and bone marrow adipose tissue

_2024-06-10_

Collaborative project between CellSight, UCSF, UC Davis, Dana Farber and Stanford University that used 18F-AraG to demonstrate a connection between neuroinflammation and adipose tissue is presented at the SNMMI 2024 in Toronto.

### Physiological Uptake of [18F]F-AraG immunoPET in Non-Small Cell Lung Cancer Patients in Japan 

_2024-06-09_

At SNMMI in Toronto, Dr. Tomomi Nobashi from Kyoto University presented the first report on the use of 18F-AraG PET/CT in Asian population.

### Emergence of novel CD3+ Macrophages in Brown Adipose Tissue Following Adrenergic Stimulation

_2024-05-05_

Dr. Hee-Don Chae reports on a unique population of CD3+F4/80+ dual lineage co-expressing cells within the interscapular brown adipose tissue that increased following chronic adrenergic stimulation.

### [18F]F-AraG PET imaging of activated T cells differentiates between acute and chronic lesions in a multiple sclerosis model

_2024-03-15_

At EMIM 2024 in Porto Dr. Caroline Guglielmetti presents findings that indicate that 18F-AraG PET may serve as a useful tool in lesion stratification, monitoring disease progression and therapy response in multiple sclerosis.

### Pharmacokinetic analysis and simplified uptake measures for tumor lesion [18F]F-AraG PET imaging in patients with non-small cell lung cancer

_2024-03-15_

Dr. Jessica E. Wijngaarden from Amsterdam UMC presents a study that validated simplified uptake measures as suitable quantifying metrics for [18F]F-AraG lesional uptake, characterized by the two-tissue irreversible model.

### [18F]F-AraG Accumulates in Metabolically Active Brown- and Bone Marrow Adipose Tissue

_2024-03-13_

The study highlighting the ability of 18F-AraG to simultaneously track activated T lymphocytes and adipocytes and allow probing both immune and adipose tissue dynamics and function is presented at EMIM 2024 in Porto.

### [18F]F-AraG PET Imaging Reveals Unique Tissue T Cell Activation Patterns Across HIV Infection States 


_2024-03-04_

At CROI 2024 in Colorado Dr. Timothy Henrich from UCSF presents a study that showed persistent T cell activation in bone marrow, pulmonary artery, and nasopharyngeal and gut tissue across a range of HIV-1 disease states.